Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar that will share insights on key considerations for pharma/biotech manufacturers on early access program strategy and implementation.
The webinar titled ` Early Access Programs in Europe: ‘A Friend or a Foe’ will be conducted by educational webinars provider Xtalks and will be held on Wednesday, September 30, 2020 at 11am EDT (4pm BST/UK). For more information or to register for this event, visit Early Access Programs in Europe: ‘A Friend or a Foe’.
Speakers include P4A’s Sophie Schmitz, managing partner and Akshay Kumar, partner. Luke Robinson, General Manager, UK, Ireland and Nordics & head of EU marketing at BioCryst Pharmaceuticals, Inc will provide the biotech industry perspective at the discussion.
In the EU, Early Access Programs enable patients to access therapies pre-commercialisation for diseases with high unmet need. Known as ‘Expanded Access Programs’ in the US, these initiatives allow for orphan drugs to be made available to patients with rare diseases before they’ve been formally approved by regulators.
While these programs can offer numerous benefits to patients, physicians and manufacturers, decisions made during their set-up can have downstream implications for access and commercialisation potential after marketing authorization.
Through a mix of case examples and direct experiences, the webinar will highlight insights into decisions made during program design, set-up, and ongoing implementation. Importantly, the speakers will recommend key considerations for manufacturers to aid the design of their Early Access Program Strategy and associated implementation plans for Europe to optimise success with future launches.
Discussing the key reasons for biotechs to attend this webinar, Akshay Kumar said: “It will help companies to make an informed decision of when is it appropriate to pursue an EAP in Europe. Also it will help them identify the key considerations that go in to EAP strategy definition and/or implementation planning with a view to optimize commercial outcomes when the drug receives marketing authorization.”
Manufacturers should attend this webinar to:
* Make informed strategic choices on EAPs
* Avoid expensive mistakes
* Optimize uptake post-launch
Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.
As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access. Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please visit P4A’s website: www.partners4access.com or email at [email protected].
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/